Alivus Life Sciences Ltd.
NSE: ALIVUS BSE: ALIVUS
Prev Close
919.75
Open Price
922
Volume
42,515
Today Low / High
919.75 / 946.8
52 WK Low / High
819 / 1225.1
Range
894 - 988
Prev Close
920.35
Open Price
922
Volume
3,707
Today Low / High
918.75 / 942.85
52 WK Low / High
827.1 / 1224
Range
892 - 986
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 940.65 (target range: 894 - 988), reflecting a change of 20.9 (2.27236%). On the BSE, it is listed at 939.1 (target range: 892 - 986), showing a change of 18.75 (2.03727%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Alivus Life Sciences Ltd. Graph
Alivus Life Sciences Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alivus Life Sciences Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 940.65, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 939.10 | 948.49 | 853.64 - 1,043.34 |
| 957.88 | 766.31 - 1,149.46 | ||
| 967.27 | 677.09 - 1,257.45 | ||
| Bearish Scenario | 939.10 | 929.71 | 836.74 - 1,022.68 |
| 920.32 | 736.25 - 1,104.38 | ||
| 910.93 | 637.65 - 1,184.21 |
Overview of Alivus Life Sciences Ltd.
ISIN
INE03Q201024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
84,515
Market Cap
112,223,661,600
Last Dividend
5
Official Website
IPO Date
2025-01-13
DCF Diff
156.38
DCF
758
Financial Ratios Every Investor Needs
Stock Dividend of ALIVUS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-01 | September 01, 25 | 5 | 5 | 2025-09-01 | 2025-09-12 | |
| 2023-10-17 | October 17, 23 | 22.5 | 22.5 | 2023-10-17 | 2023-11-08 | |
| 2023-03-24 | March 24, 23 | 21 | 21 | 2023-03-24 | 2023-03-29 | |
| 2022-09-15 | September 15, 22 | 10.5 | 10.5 | 2022-09-16 | 2022-10-26 | |
| 2021-11-22 | November 22, 21 | 10.5 | 10.5 | 2021-11-23 | 2021-12-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,371.89 Cr | 1,608.05 Cr | 763.85 Cr | 0.3220 | 0.00 Cr | 17.13 Cr | 623.80 Cr | 485.63 Cr | 39.63 | 717.15 Cr | 0.2047 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 71.06 Cr | 3,411.45 Cr | 594.08 Cr | 2,817.3720 Cr | 56.61 Cr | -14.46 Cr | 673.95 Cr | 1,045.72 Cr | 0.00 Cr | 0.00 Cr | 0.08 Cr | 470.1590 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 411.4200 Cr | -635.6580 Cr | -6.1140 Cr | 245.2330 Cr | -230.3520 Cr | 71.0620 Cr | -166.1870 Cr | 654.1310 Cr | 0.0000 Cr | 0.0000 Cr | -38.8550 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 672.89 Cr | 362.45 Cr | 310.44 Cr | 0.4614 | 211.62 Cr | 150.26 Cr | 12.25 | 231.27 Cr | 0.2233 |
| 2025-09-30 | 587.98 Cr | 333.75 Cr | 254.23 Cr | 0.4324 | 160.74 Cr | 130.03 Cr | 10.60 | 193.89 Cr | 0.2211 |
| 2025-06-30 | 601.85 Cr | 270.39 Cr | 331.46 Cr | 0.5507 | 155.25 Cr | 121.54 Cr | 9.91 | 181.30 Cr | 0.2019 |
| 2025-03-31 | 602.50 Cr | 300.87 Cr | 301.63 Cr | 0.5006 | 184.28 Cr | 141.87 Cr | 0.00 | 208.52 Cr | 0.2355 |
| 2024-12-31 | 641.84 Cr | 285.27 Cr | 356.57 Cr | 0.5555 | 175.15 Cr | 136.96 Cr | 11.18 | 200.76 Cr | 0.2134 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 19.18 Cr | 633.62 Cr | 652.80 Cr | 1,002.85 Cr | 722.51 Cr | 2,475.95 Cr | 1,122.13 Cr | 3,638.34 Cr | 622.99 Cr |
| 2025-03-31 | 71.06 Cr | 477.62 Cr | 548.68 Cr | 1,009.61 Cr | 673.95 Cr | 2,335.16 Cr | 1,045.72 Cr | 3,411.45 Cr | 594.08 Cr |
| 2024-09-30 | 446.12 Cr | 84.09 Cr | 530.20 Cr | 775.13 Cr | 689.20 Cr | 2,096.06 Cr | 945.12 Cr | 3,084.86 Cr | 546.38 Cr |
| 2024-03-31 | 301.41 Cr | 90.55 Cr | 301.41 Cr | 855.80 Cr | 666.59 Cr | 1,916.00 Cr | 904.78 Cr | 2,850.41 Cr | 518.09 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Gender: Not Specified
Year Born:
Gender: Not Specified
Year Born: 1965
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: Not Specified
Year Born:
FAQs about Alivus Life Sciences Ltd.
The CEO is Yasir Yusufali Rawjee.
The current price is ₹914.35.
The range is ₹819-1225.1.
The market capitalization is ₹11,222.37 crores.
The dividend yield is 0.55%.
The P/E ratio is 20.63.
The company operates in the Healthcare sector.
Overview of Alivus Life Sciences Ltd. (ISIN: INE03Q201024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹11,222.37 crores and an average daily volume of 84,515 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.